Purpose: Potassium supplementation thresholds in intensive care vary widely and have historically lacked strong supporting evidence.The TIGHT K trial demonstrated non-inferiority of a restrictive potassium threshold in cardiac surgical patients; applicability to general intensive care populations is unclear.Methods: Retrospective before-and-after quality improvement audit in a mixed adult intensive care unit (ICU), comparing two one-week periods before (May 2025) and after (September 2025) reducing the intravenous potassium supplementation threshold from <4.5 to <3.6 mmol/L.Results: Forty-eight patients were included (22 pre-, 26 post-guideline) with comparable baseline characteristics.Mean intravenous potassium administrations per patient fell by 17.4% (from 9.41 to 7.77 administrations per patient), and the proportion of supplementation episodes initiated at K⁺ ≥4.0 mmol/L fell from 32.9% to 11.4% (a 21.5 percentage-point absolute reduction, equivalent to a 65.2% relative reduction).Pre-supplementation potassium was lower post guideline (3.44 vs 3.83 mmol/L; p <0.001), but potassium correction (ΔK) was unchanged (p = 0.51), and arrhythmia burden did not increase.Conclusion: A restrictive potassium supplementation threshold reduced potassium use without evidence of harm in a general intensive care population, supporting wider applicability beyond cardiac surgery, although larger prospective studies are needed.
No takes yet. Share an insight, caveat, or question.
Bhalla et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: